

CORRECTION

Correction: Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Daniel J. Fullen, Nicolas Noulin, Andrew Catchpole, Hosnieh Fathi, Edward J. Murray, Alex Mann, Kingsley Eze, Ganesh Balaratnam, Daryl W. Borley, Anthony Gilbert, Rob Lambkin-Williams

Fig 11, "Mean mucus weight by day in all subjects in the Human Viral Challenge Model." is a duplicate of Fig 9, "Mean symptom score by day in symptom positive subjects in the Human Challenge Viral Model." Please view the correct Fig 11 here.



GOPEN ACCESS

Citation: Fullen DJ, Noulin N, Catchpole A, Fathi H, Murray EJ, Mann A, et al. (2016) Correction: Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model. PLoS ONE 11(6): e0157211. doi:10.1371/journal. pone.0157211

Published: June 9, 2016

Copyright: © 2016 Fullen et al. This is an open access article distributed under the terms of the <u>Creative Commons Attribution License</u>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.






Fig 11. Mean mucus weight by day in all subjects in the Human Viral Challenge Model.

doi:10.1371/journal.pone.0157211.g001

Reference

 Fullen DJ, Noulin N, Catchpole A, Fathi H, Murray EJ, Mann A, et al. (2016) Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model. PLoS ONE 11(1): e0145902. doi: 10.1371/journal.pone.0145902 PMID: 26761707